mRNA Therapeutics and mRNA Vaccines Market Report 2022: Surge in mRNA Focused Research Initiatives Bodes Well for Growth
Friday, December 16, 2022
DUBLIN, Dec. 8, 2022 /PRNewswire/ -- The "mRNA Therapeutics and mRNA Vaccines Market by Route of Administration, Therapeutic Area, and Geography: Global Trends and Industry Analysis, 2022-2035" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
Messenger ribonucleic acid (mRNA) is a type of single-stranded ribonucleic acid (RNA), which helps in transferring genetic information in order to produce proteins. The mRNA encoding instructions for protein synthesis are transferred from a strand of DNA to the ribosomes, where these instructions are translated and processed into functional proteins.
Q1. How is the research and development (R&D) activity evolving in the mRNA-based drugs industry?
mRNA therapeutics and mRNA vaccines have emerged as a promising alternative to conventional treatment approaches. Post the onset of the COVID-19 pandemic, mRNA therapeutics and mRNA vaccines have garnered significant attention as they have evolved as a revolutionary novel drug class for the treatment of COVID-19, as well as several other diseases, such as infectious diseases, oncological disorders, genetic disorders and other disorders. Subsequently, upon the approval of the first mRNA vaccine under emergency use authorization (EUA), Comirnaty, in 2020, the field has witnessed a further surge in activity.
Q2. What are the key advantages offered by mRNA therapeutics and mRNA vaccines?
The ongoing research and development efforts being undertaken in this domain are primarily being driven by the various advantages offered by these molecules, including higher biological efficacy, enhanced potent immunogenicity and versatile delivery platforms at reduced toxicity levels, over other therapeutic modalities.
Recent reports highlight the potential benefits related to the use of mRNA; for instance, such products pose no undesirable risk of inadvertent infection and insertional mutagenesis.
Q3. What are the current opportunities in the mRNA vaccines and mRNA therapeutics market?
In the past few years, the field of mRNA therapeutics and mRNA vaccines has evolved at a steady pace. In fact, a significant amount of preclinical data has been gathered and multiple human clinical trials have been initiated. Further, over the past decade, major technological innovations and substantial investments have enabled mRNA to become a promising therapeutic tool in the field of vaccine development and protein replacement therapy. With the advent of several mRNA-based technologies, there has been a rise in the development of these therapeutics to target a myriad of disease indications.
Q4. What are the recent developments and expected trends in the mRNA vaccines and mRNA therapeutics market?
Presently, over 35 companies are engaged in the evaluation of more than 195 mRNA therapeutics and mRNA vaccines, across various stages of development, for a myriad of disease indications. Further, over the coming decade, several promising leads, specifically those exhibiting enhanced efficacy, are anticipated to be commercially launched. Moreover, considering the active involvement of big pharma players, as well as new entrants, the development pipeline of mRNA drugs is likely to grow further.
Q5. What are the key challenges faced by mRNA drug developers?
Despite the numerous benefits offered by mRNA therapies, developers of these novel products often face challenges related to the stability and targeted delivery of their drug candidates. Some of the other key concerns faced by drug developers include limited availability of expertise, lack of specialized infrastructure, requirement for exorbitant capital investment, and constraints associated with ensuring compliance to good manufacturing practices (GMP). ,
Q6. What are the key value drivers in the mRNA vaccines and mRNA therapeutics market?
The key value drivers in the mRNA therapeutics and mRNA vaccines market include a significant rise in the overall healthcare expenditure, increased R&D spending, a surge in mRNA-focused research initiatives and a plethora of mRNA technological advancements in the recent past.
Key Topics Covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. MARKET OVERVIEW
5. COMPETITIVE LANDSCAPE
6. COMPANY COMPETITIVENESS ANALYSIS
7. DRUG PROFILES
8. BIG PHARMA INITIATIVES
9. START-UP HEALTH INDEXING
10. CLINICAL TRIAL ANALYSIS
11. PARTNERSHIPS AND COLLABORATIONS
12. FUNDING AND INVESTMENT ANALYSIS
13. PATENT ANALYSIS
14. MARKET FORECAST AND OPPORTUNITY ANALYSIS
15. CONCLUSION
16. INTERVIEW AND SURVEY TRANSCRIPTS
17. APPENDIX I: TABULATED DATA
18. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
Companies Mentioned
-- 8VC
-- Abu Dhabi Investment Authority
-- ACM Biolabs
-- Acuitas Therapeutics
-- Adium Pharma
-- African Union
-- AIM Vaccine
-- Albany Molecular Research
-- Alcobra
-- Aldevron
-- Alexandria Venture Investments
-- Alexion Pharmaceuticals
-- Amazon Web Services
-- Amgen
-- Arcturus Therapeutics
-- ArrowMark Partners
-- Astellas
-- Astellas Innovation Management (Subsidiary of Astellas Pharma)
-- AstraZeneca
-- Atlas Venture
-- Avidity Partners
-- Axcelead
-- Baden-Wurttemberg Supply Institution for Doctors, Dentists and
Veterinarians
-- Baidu
-- Baillie Gifford
-- Baird Capital
-- Baupost
-- Bavarian State Ministry for Economic Affairs, Regional Development and
-- Energy
-- Baxter BioPharma Solutions
-- Bayer
-- BB Biotech
-- BeiGene
-- Bill & Melinda Gates Foundation
-- Biomedical Advanced Research and Development Authority
-- BioNTech
-- BIORCHESTRA
-- Biovac
-- Black Forest SICAV-SIF
-- BlueIO
-- Boehringer Ingelheim
-- Boehringer Ingelheim Venture Fund
-- BofA Securities
-- Boston Biotech Ventures
-- Brookside Capital
-- BVCF Management
-- BVF Partners
-- Cancer Research Institute
-- CanSino Biologics
-- Carlos III National Center for Cardiovascular Research (CNIC)
-- Catalent
-- CDH Investments
-- Central Innovation Programme for SMEs (ZIM)
-- Changhai Hospital
-- Charles River
-- Chartwave
-- Chiesi Farmaceutici
-- Chimeron Bio
-- China Growth Capital
-- China Merchants Medical and Health Industry Equity Fund
-- cmRNAbone consortium
-- Coalition for Epidemic Preparedness Innovations (CEPI)
-- Codex DNA
-- Colt Ventures
-- ConserV Bioscience
-- Continental Grain Company
-- Coppel family
-- Cormorant Asset Management
-- Co-win Ventures
-- CPE Yuanfeng
-- And More
For more information about this report visit https://www.researchandmarkets.com/r/4yxva2
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/mrna-therapeutics-and-mrna-vaccines-market-report-2022-surge-in-mrna-focused-research-initiatives-bodes-well-for-growth-301698644.html
SOURCE Research and Markets
|
|
|
|
|
 |
Sup AI Sets New Benchmark Record with 52.15% on Humanity's Last Exam | Jan 22, 2026
|
|
Weekly Recap: 11 Tech Press Releases You Need to See | Jan 22, 2026
|
|
DEADLINE ANNOUNCED FOR 2026 NEW TOP-LEVEL DOMAIN APPLICATIONS | Jan 22, 2026
|
|
Trigent Partners with WeWork India to Expand its GCC Footprint | Jan 22, 2026
|
|
Skunk Works® and XTEND Expand Joint All Domain Command and Control for Advanced Mission Execution | Jan 22, 2026
|
|
Altair HyperWorks 2026 Delivers Design and Simulation at Scale with AI | Jan 22, 2026
|
|
Exia Labs Brings Keystone to the U.S. Navy via DIU's Blue Object Management Challenge | Jan 22, 2026
|
|
Marketing Evolution Announces New Investment Led by Insight Partners to Power AI-Ready Marketing Data for the Agentic Era | Jan 22, 2026
|
|
Genpact Named a Leader in ISG Provider Lens(TM) 2025 for Insurance GCCs and Agentic AI Services | Jan 22, 2026
|
|
Glasswall Brings Defense-Level File Sanitization to Every Government Agency and Business Using Microsoft 365 | Jan 22, 2026
|
|
|
